Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

U.S. Food and Drug Administration Approves Cangene's VARIZIG®

Published: Thursday, January 10, 2013
Last Updated: Wednesday, January 09, 2013
Bookmark and Share
Commercial distribution of product is expected in early March of 2013.

Cangene Corporation has announced that the United States Food and Drug Administration has approved VARIZIG® [Varicella Zoster Immune Globulin (Human)] for post-exposure prophylaxis of varicella (chickenpox) in high risk patient groups including immunocompromised children, newborns and pregnant women.

VARIZIG is intended to reduce the severity of chickenpox infections in these patients.

VARIZIG is a hyperimmune product that contains antibodies specific for the Varicella zoster virus which causes the viral infection known as chickenpox.

VARIZIG is approved in Canada and was previously made available in the United States under an investigational new drug (IND) Expanded Access Protocol.

Through the expanded access program, VARIZIG was available for patients at risk of severe complications of varicella, to address the unmet need in this population.

The Expanded Access Protocol will remain active until commercial product is available for distribution which is expected in early March of 2013.

VARIZIG will continue to be distributed exclusively by FFF Enterprises, Inc., a leading biopharmaceutical supplier.

"The approval of VARIZIG in the United States marks an important milestone in Cangene's history" says John A. Sedor, President and Chief Executive Officer of Cangene.

"While VARIZIG services a small niche infectious disease market, the approval of the product in the United States adds a fourth product to our commercial portfolio and reflects our patient focused strategy by addressing an ongoing medical need" added Mr. Sedor.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cangene Receives Approval for WinRho
Company has received marketing authorization approval in Portugal from INFARMED.
Monday, September 23, 2013
Cangene Awarded Biodefence Contract for AIGIV
Company has been awarded a multiple award indefinite delivery/indefinite quantity contract.
Friday, September 20, 2013
Cangene Granted Exclusive U.S. Commercialization Rights for episil® by Camurus AB
Plans product launch in October 2012.
Tuesday, July 10, 2012
Cangene Hires Vice President, Business Development
Mr. Kevin G. Taylor joins the new position of Vice President.
Wednesday, March 28, 2012
Cangene Reports Second Quarter 2012 Results
Company reports financial results, ended on January 31, 2012.
Thursday, March 15, 2012
Scientific News
Breaking Through the Barriers to Lab Innovation
Here we examine the drivers behind the move for greater innovation, the challenges and current trends in laboratory informatics, and the tools that can be used to break these barriers.
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Fruit Fly Pheromone Flags Great Real Estate for Starting a Family
Finding could aid efforts to control mosquito-borne diseases like malaria by manipulating odorants
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Adult High Blood Pressure Risk Identifiable in Childhood
Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new University of Otago research suggests.
Analyzing Protein Structures in Their Native Environment
Enhanced-sensitivity NMR could reveal new clues to how proteins fold.
Supercoiled DNA is Far More Dynamic Than the “Watson-Crick” Double Helix
Researchers have imaged in unprecedented detail the three-dimensional structure of supercoiled DNA, revealing that its shape is much more dynamic than the well-known double helix.
Mini-kidneys Successfully Grown from Stem Cells
Researchers from Murdoch Childrens Research Institute have perfected a method of turning stem cells into mini-kidneys for use in drug screening, disease modelling and cell therapy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos